Dechra Pharmaceuticals PLC (DPHAY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Dechra Pharmaceuticals PLC (DPHAY) trades at $98.00 with AI Score 48/100 (Grade C). Dechra Pharmaceuticals PLC is a global veterinary pharmaceutical company focused on developing, manufacturing, and marketing products for companion animals and livestock. Market cap: $5.58B, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for DPHAY: DPHAY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DPHAY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
DPHAY: the 1 perspectives are evenly split.
How is this calculated? →Dechra Pharmaceuticals PLC (DPHAY) Healthcare & Pipeline Overview
Dechra Pharmaceuticals PLC is a global veterinary pharmaceutical company specializing in the development, manufacturing, and marketing of veterinary pharmaceuticals and related products. With a focus on endocrinology, dermatology, analgesia, and pet nutrition, Dechra serves veterinarians across Europe, North America, and other international markets, offering a comprehensive portfolio for companion animals and livestock.
What Is the Investment Thesis for DPHAY?
Dechra Pharmaceuticals PLC presents a notable research candidate within the growing veterinary pharmaceutical market. The company's diverse product portfolio, spanning various therapeutic areas and animal species, provides a stable revenue base. A key value driver is Dechra's focus on innovation and R&D, which allows it to introduce new and improved products to meet evolving veterinary needs. The company's established presence in Europe and North America, coupled with its expansion into international markets, offers significant growth potential. The aging pet population and increasing pet ownership are ongoing catalysts driving demand for veterinary pharmaceuticals. However, potential risks include regulatory changes, competition from other pharmaceutical companies, and fluctuations in currency exchange rates. With a market capitalization of $5.58B and a dividend yield of 0.32%, Dechra offers a blend of growth and income potential.
Based on FMP financials and quantitative analysis
DPHAY Key Highlights
- Dechra Pharmaceuticals PLC operates with a gross margin of 56.0%, indicating strong pricing power and efficient cost management in its manufacturing and distribution processes.
- The company's beta of 0.75 suggests lower volatility compared to the overall market, potentially offering a more stable investment during market fluctuations.
- Dechra's dividend yield of 0.32% provides a modest income stream for investors, adding to the overall investment appeal.
- The company operates across three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development, diversifying its revenue streams and reducing reliance on any single market or product.
- Dechra's focus on veterinary pharmaceuticals and related products caters to the growing demand for animal health solutions, driven by increasing pet ownership and spending on pet care.
Who Are DPHAY's Competitors?
DPHAY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ABCZF Abcam plc | $22.25 | +0.68% | $5.12B | 46 |
| ANHGY Mediclinic International plc | $5.49 | +0.00% | $4.05B | 44 |
| ASPHF Ascentage Pharma Group International | $4.53 | +0.00% | $1.69B | 51 |
| CAKFY McKesson Europe AG | $4.10 | +0.00% | $5.37B | 35 |
| GALNF Galenica AG | $115.00 | +0.00% | $5.73B | 46 |
| ORINY Orion Oyj | $38.86 | +0.00% | $21.87B | 64 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 64 |
| ORINF Orion Oyj | $82.75 | +0.00% | $11.66B | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DPHAY's Key Strengths?
- Diverse product portfolio across multiple therapeutic areas.
- Global presence with operations in key markets.
- Strong brand reputation and established relationships with veterinarians.
- Focus on innovation and research and development.
What Are DPHAY's Weaknesses?
- Negative profit margin of -3.7% indicates potential profitability challenges.
- High P/E ratio of -157.24 suggests the stock may be overvalued.
- Dependence on wholesaler and distributor networks.
- Exposure to regulatory risks and potential product recalls.
What Could Drive DPHAY Stock Higher?
- Increasing pet ownership and spending on pet care are driving demand for veterinary pharmaceuticals.
- Potential regulatory approvals for new products in the pipeline.
- Expansion into emerging markets with growing pet populations.
- Strategic acquisitions to expand product portfolio and geographic reach.
What Are the Key Risks for DPHAY?
- Negative return on equity (-3.9%) — the business is not currently generating profit on shareholder capital.
- Intense competition from established pharmaceutical companies.
- Fluctuations in currency exchange rates.
- Changes in regulatory requirements and potential product recalls.
- Economic downturns that could impact pet ownership and spending on pet care.
- Negative profit margin of -3.7% indicates potential profitability challenges.
What Are the Growth Opportunities for DPHAY?
- Expansion into Emerging Markets: Dechra has the opportunity to expand its presence in emerging markets, such as Asia and Latin America, where the demand for veterinary pharmaceuticals is growing rapidly. These markets offer significant growth potential due to increasing pet ownership, rising disposable incomes, and a growing awareness of animal health. By establishing partnerships with local distributors and tailoring its product offerings to meet the specific needs of these markets, Dechra can tap into a new source of revenue and expand its global footprint. This expansion could contribute an additional 10-15% to revenue growth over the next 3-5 years.
- Development of Novel Therapies: Dechra can invest in the development of novel therapies for unmet needs in the veterinary pharmaceutical market. By focusing on innovative research and development, the company can create differentiated products that address specific animal health challenges and command premium pricing. This includes exploring new drug formulations, delivery methods, and therapeutic areas. Successful development and commercialization of novel therapies could drive significant revenue growth and enhance Dechra's competitive position. The market for novel veterinary therapies is estimated to reach $5 billion by 2030.
- Strategic Acquisitions: Dechra can pursue strategic acquisitions to expand its product portfolio, geographic reach, and technological capabilities. By acquiring companies with complementary products or technologies, Dechra can strengthen its market position and accelerate its growth. This includes targeting companies with expertise in specific therapeutic areas, such as oncology or cardiology, or companies with a strong presence in emerging markets. Strategic acquisitions can provide Dechra with access to new markets, products, and technologies, driving revenue growth and enhancing its competitive advantage. The timeline for potential acquisitions is ongoing.
- Increased Focus on Pet Nutrition: Dechra can capitalize on the growing trend of pet owners seeking high-quality nutrition products for their pets. By expanding its pet nutrition product line and focusing on premium ingredients and formulations, Dechra can attract health-conscious pet owners and drive revenue growth. This includes developing products that address specific dietary needs, such as weight management, allergy relief, and digestive health. The global pet nutrition market is estimated to reach $100 billion by 2027, providing a significant opportunity for Dechra to expand its presence in this segment. The timeline for increased pet nutrition focus is ongoing.
- Leveraging Digital Technologies: Dechra can leverage digital technologies to enhance its customer engagement, improve its operational efficiency, and drive revenue growth. This includes developing online platforms for veterinarians to access product information, order products, and connect with Dechra's sales and support teams. It also includes using data analytics to gain insights into customer behavior and preferences, enabling Dechra to tailor its product offerings and marketing efforts. By embracing digital technologies, Dechra can improve its customer experience, streamline its operations, and drive revenue growth. The implementation of digital technologies is an ongoing process.
What Opportunities Does DPHAY Have?
- Expansion into emerging markets with growing pet populations.
- Development of novel therapies for unmet needs in the veterinary market.
- Strategic acquisitions to expand product portfolio and geographic reach.
- Increased focus on pet nutrition and premium pet food products.
What Threats Does DPHAY Face?
- Intense competition from established pharmaceutical companies.
- Fluctuations in currency exchange rates.
- Changes in regulatory requirements and potential product recalls.
- Economic downturns that could impact pet ownership and spending on pet care.
What Are DPHAY's Competitive Advantages?
- Strong brand reputation and established relationships with veterinarians.
- Diverse product portfolio spanning various therapeutic areas and animal species.
- Global presence with operations in Europe, North America, and other international markets.
- Focus on innovation and research and development.
- Stringent regulatory compliance, creating barriers to entry for competitors.
What Does DPHAY Do?
Dechra Pharmaceuticals PLC, incorporated in 1997 and headquartered in Northwich, United Kingdom, is a global veterinary pharmaceutical company dedicated to enhancing animal health and well-being. The company develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. Dechra operates through three key segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. Its diverse product portfolio includes endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats. Additionally, Dechra offers water-soluble antibiotics, poultry vaccines, and pain management solutions for poultry, pigs, and cattle, as well as lameness and pain management products for horses and ponies. Beyond pharmaceuticals, Dechra provides pet nutrition products designed to support cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. The company also distributes veterinary pharmaceuticals and equipment, offers financial services, markets pet diets, and develops, regulates, manufactures, and markets crop protection products. Dechra markets its products through a network of wholesalers and distributors, reaching customers in the United Kingdom, Germany, the rest of Europe, the United States, and other international markets. Dechra's commitment to innovation and quality has established it as a trusted partner for veterinarians globally.
What Products and Services Does DPHAY Offer?
- Develops veterinary pharmaceuticals for companion animals and livestock.
- Manufactures a range of products, including endocrinology, dermatology, and analgesia medications.
- Regulates its products to meet stringent quality and safety standards.
- Markets its products through wholesaler and distributor networks.
- Sells veterinary pharmaceuticals and related products to veterinarians.
- Provides pet nutrition products for various therapeutic conditions.
- Offers financial services related to its products and services.
- Develops and markets crop protection products.
How Does DPHAY Make Money?
- Develops and manufactures veterinary pharmaceuticals and related products.
- Markets and sells these products through a network of wholesalers and distributors to veterinarians.
- Generates revenue from the sale of pharmaceuticals, pet nutrition products, and related services.
- Invests in research and development to create new and innovative products.
What Industry Does DPHAY Operate In?
Dechra Pharmaceuticals PLC operates within the global veterinary pharmaceutical market, which is experiencing steady growth driven by factors such as increasing pet ownership, rising disposable incomes, and a growing awareness of animal health. The market is characterized by intense competition among established players and emerging companies. Dechra differentiates itself through its diverse product portfolio, global presence, and focus on innovation. The industry is also subject to stringent regulatory requirements, which can create barriers to entry and impact product development timelines. According to industry reports, the global veterinary pharmaceutical market is projected to reach $45 billion by 2028, growing at a CAGR of 6-8%.
Who Are DPHAY's Key Customers?
- Veterinarians who prescribe and administer Dechra's products to animals.
- Wholesalers and distributors who purchase and distribute Dechra's products to veterinary clinics.
- Pet owners who purchase pet nutrition products for their animals.
- Livestock farmers who use Dechra's products to maintain the health of their animals.
Company Profile
Dechra Pharmaceuticals PLC operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Northwich, GB. The company is led by CEO Ian D. Page. DPHAY has traded publicly since 2018.
F-Score 6/9Financial Health
Dechra Pharmaceuticals PLC's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.55 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE -4%Key Financial Metrics
Return on equity for Dechra Pharmaceuticals PLC stands at -3.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.8%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.85 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.6%, the inverse of the P/E and a quick read on earnings relative to price.
DPHAY Valuation & Market Position
With a $5.58B market cap, Dechra Pharmaceuticals PLC sits in the mid-cap segment of the market. Relative to its peer group, DPHAY's quantitative score of 48/100 is roughly in line with the peer average of 44/100.
DPHAY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Diverse product portfolio across multiple therapeutic areas.
- Global presence with operations in key markets.
- Strong brand reputation and established relationships with veterinarians.
- Focus on innovation and research and development.
Bear Case
- Negative profit margin of -3.7% indicates potential profitability challenges.
- High P/E ratio of -157.24 suggests the stock may be overvalued.
- Dependence on wholesaler and distributor networks.
- Exposure to regulatory risks and potential product recalls.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
DPHAY Latest News
No recent news available for DPHAY.
DPHAY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DPHAY.
Price Targets
Wall Street price target analysis for DPHAY.
DPHAY MoonshotScore
What does this score mean?
The MoonshotScore rates DPHAY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ian D. Page
CEO
Ian D. Page serves as the Chief Executive Officer of Dechra Pharmaceuticals PLC. His career spans several decades in the pharmaceutical industry, with a focus on animal health. Prior to joining Dechra, he held various leadership positions at leading pharmaceutical companies, where he gained extensive experience in sales, marketing, and business development. He has a strong track record of driving growth and innovation in the animal health sector. His expertise includes strategic planning, product development, and international expansion.
Track Record: Under Ian Page's leadership, Dechra Pharmaceuticals PLC has experienced significant growth and expansion. He has overseen the successful launch of several new products and the expansion of the company's global footprint. He has also played a key role in driving innovation and improving operational efficiency. During his tenure, Dechra has strengthened its market position and enhanced its reputation as a leading veterinary pharmaceutical company.
Dechra Pharmaceuticals PLC ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. DPHAY is a Level 1 ADR, meaning it trades over-the-counter (OTC) rather than on a major exchange. This allows U.S. investors to invest in Dechra Pharmaceuticals PLC without directly dealing with foreign markets.
- Home Market Ticker: London Stock Exchange, United Kingdom
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: DPHA
DPHAY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Dechra Pharmaceuticals PLC (DPHAY) may have limited regulatory oversight and disclosure requirements compared to companies listed on major exchanges like the NYSE or NASDAQ. Companies in this tier often have minimal financial reporting and may not meet the listing standards of higher-tier exchanges, potentially leading to increased risks for investors due to lack of transparency and readily available information.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight and disclosure requirements on the OTC market.
- Potential for lower trading volumes and wider bid-ask spreads.
- Increased price volatility due to limited liquidity.
- Risk of fraud or manipulation due to less stringent listing standards.
- Uncertainty regarding the accuracy and reliability of financial information.
- Verify the company's registration and legal status.
- Obtain and review any available financial reports and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC securities.
- Consult with a financial advisor before making any investment decisions.
- Check for any news or regulatory actions related to the company.
- Established operating history as Dechra Pharmaceuticals PLC since 1997.
- Global presence with operations in multiple countries.
- Presence in the veterinary pharmaceutical market, a regulated industry.
- Availability of some information through its ADR status, even if OTC.
- Employee count of 2457 suggests a substantial operation.
DPHAY Healthcare Stock FAQ
What does Dechra Pharmaceuticals PLC do?
Dechra Pharmaceuticals PLC is a global veterinary pharmaceutical company that develops, manufactures, and markets a wide range of products for companion animals and livestock. Its portfolio includes pharmaceuticals, pet nutrition products, and related services, addressing various therapeutic areas such as endocrinology, dermatology, and analgesia. The company operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development, serving veterinarians and pet owners across Europe, North America, and other international markets. Dechra's commitment to innovation and quality has established it as a trusted partner in the animal health industry.
What are the main risks for DPHAY?
Dechra Pharmaceuticals PLC faces several risks, including intense competition from established pharmaceutical companies, fluctuations in currency exchange rates, and changes in regulatory requirements. The company's negative profit margin of -3.7% indicates potential profitability challenges. Additionally, economic downturns could impact pet ownership and spending on pet care, affecting demand for Dechra's products. As an ADR traded OTC, DPHAY also faces risks related to liquidity, transparency, and regulatory oversight. Investors should carefully consider these risks before investing in DPHAY.
What are the key growth opportunities for DPHAY in healthcare?
Dechra Pharmaceuticals PLC navigates regulatory approval processes by adhering to stringent quality and safety standards set by regulatory agencies such as the FDA in the United States and the EMA in Europe. The company invests in research and development to ensure its products meet these standards and comply with all applicable regulations. Dechra maintains a dedicated regulatory affairs team that monitors changes in regulations and works to ensure compliance. The company's track record of regulatory compliance has enabled it to successfully bring new products to market and maintain its presence in key markets.
What are the key factors to evaluate for DPHAY?
Dechra Pharmaceuticals PLC (DPHAY) holds an AI score of 48/100 (low). Not financial advice.
How frequently does DPHAY data refresh on this page?
DPHAY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven DPHAY's recent stock price performance?
Dechra Pharmaceuticals PLC (DPHAY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio across multiple therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DPHAY overvalued or undervalued right now?
Valuing Dechra Pharmaceuticals PLC (DPHAY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying DPHAY?
Before investing in Dechra Pharmaceuticals PLC (DPHAY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the latest available information.
- Analyst consensus and AI analysis are pending.
- OTC market data may be limited or unreliable.